TYPE-2 HUMAN IMMUNODEFICIENCY VIRUS (HIV-2) INFECTION IN THE USSR

被引：0
|
作者：
POKROVSKY, VV
SUVOROVA, ZK
MANGUSHEV, TN
机构：
来源：
ZHURNAL MIKROBIOLOGII EPIDEMIOLOGII I IMMUNOBIOLOGII | 1988年 / 10期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：18 / &
相关论文
共 50 条
  • [31] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 (HIV-2) TRANSACTIVATOR (TAT) - FUNCTIONAL DOMAINS AND THE SEARCH FOR TRANSDOMINANT NEGATIVE MUTANTS
    ARYA, SK
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (09) : 839 - 848
  • [32] CLINICAL, HEMATOLOGIC, AND IMMUNOLOGICAL CROSS-SECTIONAL EVALUATION OF INDIVIDUALS EXPOSED TO HUMAN IMMUNODEFICIENCY VIRUS TYPE-2 (HIV-2)
    MARLINK, RG
    RICARD, D
    MBOUP, S
    KANKI, PJ
    ROMETLEMONNE, JL
    NDOYE, I
    DIOP, K
    SIMPSON, MA
    GRECO, F
    CHOU, MJ
    DEGRUTTOLA, V
    HSIEH, CC
    BOYE, C
    BARIN, F
    DENIS, F
    MCLANE, MF
    ESSEX, M
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1988, 4 (02) : 137 - 148
  • [33] DIDEOXYNUCLEOSIDES ARE LESS INHIBITORY INVITRO AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 (HIV-2) THAN AGAINST HIV-1
    RICHMAN, DD
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (12) : 1879 - 1881
  • [34] Human Immunodeficiency Virus Type 2 (HIV-2) EU-Supporting Standardized HIV-2 Drug Resistance Interpretation: An Update
    Charpentier, Charlotte
    Berzow, Dirk
    Le Hingrat, Quentin
    Kaiser, Rolf
    Gomes, Perpetua
    Miranda, Ana Claudia
    Damond, Florence
    Ghosn, Jade
    van Kampen, Jeroen J. A.
    Jensen, Bjoern-Erik Ole
    Boehm, Michael
    Wensing, Annemarie M. J.
    Descamps, Diane
    Obermeier, Martin
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [35] MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A REPLICATION COMPETENT HUMAN IMMUNODEFICIENCY TYPE-2 (HIV-2) PROVIRAL CLONE
    FRANCHINI, G
    FARGNOLI, KA
    GIOMBINI, F
    JAGODZINSKI, L
    DEROSSI, A
    BOSCH, M
    BIBERFELD, G
    FENYO, EM
    ALBERT, J
    GALLO, RC
    WONGSTAAL, F
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) : 2433 - 2437
  • [36] Computational studies of inhibitor binding to human immunodeficiency virus, Type 2 (HIV-2) protease
    Summay, Russell
    Waingeh, Victor
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [37] Variability of human immunodeficiency virus type 2 (HIV-2) infecting patients living in France
    Damond, F
    Apetrei, C
    Robertson, DL
    Souquière, S
    Leprêtre, A
    Matheron, S
    Plantier, JC
    Brun-Vézinet, F
    Simon, F
    VIROLOGY, 2001, 280 (01) : 19 - 30
  • [38] HUMORAL AND CELL-MEDIATED-IMMUNITY IN RHESUS MACAQUES INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 (HIV-2) MUTANTS
    ABIMIKU, AG
    FRANCHINI, G
    MARKHAM, PD
    GARD, E
    GALLO, RC
    ROBERTGUROFF, M
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (05) : 900 - 900
  • [39] First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)
    Matheron, Sophie
    Descamps, Diane
    Gallien, Sebastien
    Besseghir, Amel
    Sellier, Pierre
    Blum, Laurent
    Mortier, Emmanuel
    Charpentier, Charlotte
    Tubiana, Roland
    Damond, Florence
    Peytavin, Gilles
    Ponscarme, Diane
    Collin, Fideline
    Brun-Vezinet, Francoise
    Chene, Genevieve
    CLINICAL INFECTIOUS DISEASES, 2018, 67 (08) : 1161 - 1167
  • [40] Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants
    Smith, Robert
    Raugi, Dana
    Nixon, Robert
    Seydi, Moussa
    Margot, Nicolas
    Callebaut, Christian
    Gottlieb, Geoffrey
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (05): : 1290 - 1294
12345